Literature DB >> 9874431

Management of the clinically positive neck in organ preservation for advanced head and neck cancer.

P Dagum1, H A Pinto, J P Newman, J P Higgins, D J Terris, D R Goffinet, W E Fee.   

Abstract

BACKGROUND: To investigate clinicopathologic predictive criteria for the optimal management of neck metastases in patients with advanced head and neck cancers treated with combined chemoradiotherapy.
METHODS: Prospective study, 48 patients. Mean length follow-up, 23 months.
RESULTS: Neck stage predicted neck response to chemoradiotherapy; N3 necks showed more partial responses (P = 0.04), and N1 necks showed more complete responses (P = 0.12). Primary tumor site strongly predicted the pathologic response found on neck dissection in patients with a clinical partial response (cPR) following chemoradiotherapy. There was no difference in survival between patients with a clinical complete response (cCR) after chemoradiotherapy, and patients with a pathologic complete response (pCR) after neck dissection (P = 0.20); however, when grouped together, these patients survived longer than did patients with a pPR at neck dissection (P = 0.06).
CONCLUSIONS: Clinical response to induction chemotherapy is a poor predictor of ultimate neck control. Induction chemotherapy followed by chemoradiotherapy, and planned neck dissection for patients with persistent cervical lymphadenopathy, provides good regional control.

Entities:  

Mesh:

Year:  1998        PMID: 9874431     DOI: 10.1016/s0002-9610(98)00240-2

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  2 in total

1.  Planned neck dissection following radiation treatment for head and neck malignancy.

Authors:  J F Dautremont; M K Brake; G Thompson; J Trites; R D Hart; S M Taylor
Journal:  Int J Otolaryngol       Date:  2012-09-24

2.  Planned neck dissection following chemo-radiotherapy in advanced HNSCC.

Authors:  Tejpal Gupta; Jai Prakash Agarwal
Journal:  Int Semin Surg Oncol       Date:  2004-09-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.